Rna Diagnostics Inc. announced today that Dr. Matthew P. Goetz, Consultant and Professor at Mayo Clinic, Rochester, MN has been appointed to the company’s Clinical Advisory Board (CAB).
“Dr. Goetz brings a wealth of scientific knowledge and clinical trial experience in breast cancer to Rna Diagnostics,” […]
Rna Diagnostics announced the launch of an international prospective clinical trial to validate the RNA Disruption Assay™ (RDA™) as a tool for treatment management of primary breast cancer. BREVITY (Breast Cancer Response EValuation for Individualized TherapY) will include 500+ patients with invasive breast cancer, scheduled […]
A new study provides further evidence that the Rna Disruption Assay™ (RDA™) may be a useful tool to predict the clinical outcome of neoadjuvant chemotherapy in breast cancer patients. RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth […]
April Newsletter 2016
APRIL 27, 2016
In this issue: an interview with the new CEO, patient accrual updates and more…
Rna Diagnostics Inc. appoints
Dr. Jeremy Bridge-Cook President and CEO
Dr. Ken Pritzker, on behalf of the Board of Directors of Rna Diagnostics Inc., is pleased to announce the appointment of Dr. Jeremy Bridge-Cook to the position of President and Chief Executive Officer of Rna Diagnostics Inc. […]
Rna Diagnostics announces the publication of a study on February 24 2016 in the journal BMC Cancer entitled RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines. The study concludes that RNA disruption, as assessed by the RNA Disruption […]
Rna Diagnostics Inc. announced today that Paul Lucas, an accomplished veteran of the Life Sciences industry, has joined the Company’s Board of Directors.
“Paul brings a wealth of proven business and Life Science innovation insight to Rna Diagnostics,” said Dr. Ken Pritzker, President and CEO of […]
The Ontario Institute for Cancer Research and MaRS Discovery District hosted an event for World Cancer Day under the banner of “Breaking the Mold: Rethinking the Cancer System.” Hosted by André Picard, Health Columnist of The Globe and Mail, the panel consisted of leading Cancer […]
Rna Diagnostics Inc announced today a new study to investigate RDA as a predictor for chemotherapy efficacy in canine lymphoma in partnership with University of Guelph Institute for Comparative Cancer Investigation and the Mona Campbell Centre for Animal Cancer at the Ontario Veterinary College. This […]
While the primary focus of RNA Disruption Assay (RDA) continues to be breast cancer chemotherapy management, it is rapidly evolving into a platform technology that will be utilized in the management of treatments across multiple cancers. RDA is now being employed in clinical trials for […]
